2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1755

Burden of Illness Associated with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States
Abstract Number: 288

Burden of Illness of Treating Patients with Pemphigus vulgaris
Abstract Number: 2251

Calcific Tendonitis of the Rotator Cuff: Do We Need Steroid Injection after Ultrasound Guided Percutaneous Lavage? Results of a 12-Months Double-Blind Randomized Controlled Study
Abstract Number: 2980

Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus
Abstract Number: 2026

Calcium Crystal-Mediated Netosis in Juvenile Dermatomyositis and Anti-RNP+ Overlap Syndrome with Skin Involvement
Abstract Number: 1283

Calcium Pyrophosphate Crystal Deposition in a Cohort of 48 Patients with Gitelman Syndrome
Abstract Number: 139

Calcium/Calmodulin-Dependent Protein Kinase 4 Promotes GLUT1-Dependent Glycolysis in Systemic Lupus Erythematosus
Abstract Number: 1139

Can Body Composition Explain the Sex Disparity in Risk of Osteoarthritis?
Abstract Number: 650

Can Disease Activity in Patients with Psoriatic Arthritis be Adequately Assessed By a Modified Disease Activity Index for Psoriatic Arthritis (DAPSA) Based on 28 Joints?
Abstract Number: 740

Can Monocyte Chemo-Attractant Protein-1differentiate Different Histological Classes in Lupus Nephritis?
Abstract Number: 2915

Can Passively-Collected Phone Behavior Determine Rheumatic Disease Activity?
Abstract Number: 1258

Can Patients Enter Medical History Data By Self-Report Directly into an Electronic Medical Record (EMR)? “Private Medical History” (PMH) Software for Physician Report in EMR Format and Patient Storage to Correct and Update Medical History for Any EMR
Abstract Number: 2229

Can We Predict Inadequate Response to Allopurinol Dose Escalation? Analysis of a Randomized Controlled Trial
Abstract Number: 1164

Canadians’ Views about Using Big Data in Health Research from a National Online Survey: A Partnership of Patient-Consumers and Researchers
Abstract Number: 1325

Canakinumab Treatment in Adult-Onset Still’s Disease: Case Series

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].